Drug intelligence / Profile preview

letrozole + leuprolide acetate + triptorelin acetate

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intramuscular, Subcutaneous

Overview

A combination therapy consisting of letrozole (an aromatase inhibitor) with leuprolide acetate and triptorelin acetate (both GnRH analogs). This combination is used for hormone receptor-positive breast cancer treatment in premenopausal women, where the GnRH analogs provide ovarian suppression while letrozole inhibits estrogen production. The combination creates a more intense estrogen suppression than using tamoxifen with either GnRH analog alone.

Targets

GnRHR (Gonadotropin-releasing hormone receptor)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on letrozole + leuprolide acetate + triptorelin acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on letrozole + leuprolide acetate + triptorelin acetate.

Explore the full profile